Deutsche Bank AG Raises Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Deutsche Bank AG raised its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 47.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 60,714 shares of the company's stock after buying an additional 19,540 shares during the quarter. Deutsche Bank AG owned about 0.08% of SpringWorks Therapeutics worth $2,194,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Huntington National Bank lifted its stake in shares of SpringWorks Therapeutics by 38.2% in the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after acquiring an additional 192 shares during the period. AlphaQuest LLC lifted its stake in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock worth $36,000 after acquiring an additional 414 shares during the period. Barclays PLC lifted its stake in shares of SpringWorks Therapeutics by 0.3% in the 4th quarter. Barclays PLC now owns 156,123 shares of the company's stock worth $5,641,000 after acquiring an additional 447 shares during the period. Virtus ETF Advisers LLC grew its stake in shares of SpringWorks Therapeutics by 7.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company's stock worth $327,000 after purchasing an additional 622 shares during the period. Finally, KBC Group NV grew its stake in shares of SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after purchasing an additional 978 shares during the period.

SpringWorks Therapeutics Stock Performance

SpringWorks Therapeutics stock traded up $0.21 during midday trading on Friday, reaching $46.48. 5,929,377 shares of the company were exchanged, compared to its average volume of 2,173,976. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $62.00. The company has a market capitalization of $3.50 billion, a price-to-earnings ratio of -13.36 and a beta of 0.77. The firm's 50-day simple moving average is $43.57 and its 200-day simple moving average is $42.76.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The firm had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. On average, analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on SWTX shares. Barclays reiterated an "equal weight" rating and issued a $47.00 price objective (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. TD Cowen restated a "hold" rating and set a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th. Guggenheim restated a "neutral" rating and set a $47.00 target price on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Evercore ISI downgraded SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $47.00 price objective (down from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $52.57.

Insider Buying and Selling at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $54.23, for a total value of $1,084,600.00. Following the transaction, the chief operating officer now owns 169,712 shares in the company, valued at $9,203,481.76. This trade represents a 10.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Saqib Islam sold 49,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the sale, the chief executive officer now directly owns 954,869 shares of the company's stock, valued at $51,792,094.56. This represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.83% of the stock is owned by company insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.